Company news
Kamada Ltd. (NASDAQ:KMDA) news
Kamada Ltd. news releases on 6ix. Latest, Mar 3, 2021: Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood…
Press releases — page 3
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.
March 2, 2021
Kamada Files Annual Report for the Year Ended December 31, 2020
February 23, 2021
Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities
February 9, 2021
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021
February 2, 2021
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA
January 31, 2021
Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
January 12, 2021
Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition
January 4, 2021
Kamada Added to the NASDAQ Biotechnology Index
December 20, 2020
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development
November 10, 2020
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
November 3, 2020
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
October 18, 2020
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
October 6, 2020
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
September 7, 2020
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective
August 18, 2020
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position
August 11, 2020
Kamada Announces Changes to its Board of Directors
August 11, 2020
Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
August 9, 2020
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
August 4, 2020